KALV — Kalvista Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Kalvista Pharmaceuticals Enters Into Licensing Agreement With Pendopharm To Commercialize Sebetralstat For Hae In Canada
KalVista falls as Endpoints News reports FDA commissioner sought rejection of drug
U.S. STOCKS ON THE MOVE-Hinge Health, MNTN, Reddit
U.S. STOCKS ON THE MOVE-Eaton, Roku, PayPal
U.S. STOCKS ON THE MOVE-EchoStar, T1 Energy, Smurfit Westrock
U.S. STOCKS ON THE MOVE-EchoStar, T1 Energy, Smurfit Westrock
KalVista falls as FDA extends swelling disorder drug review
US FDA extends review of KalVista's swelling disorder drug due to heavy workload (updated)
Brief: Kalvista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date For Sebetralstat NDA
US FDA extends review of KalVista's swelling disorder drug due to heavy workload
Brief: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Brief: Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan
Brief: KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31 - Earnings Summary
Brief: Kalvista Pharmaceuticals Q3 Net Income USD -44.262 Million
Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a share - Earnings Preview
Brief: Kalvista Appoints Jeb Ledell As Chief Operating Officer
Kalvista Pharmaceuticals Inc reports results for the quarter ended October 31 - Earnings Summary
Brief: Kalvista Pharmaceuticals Q2 Net Income USD -42.268 Million